Join to View Full Profile
12902 Usf Magnolia DrTampa, FL 33612
Phone+1 813-745-7365
Fax+1 813-449-8618
Dr. Pidala is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General HospitalFellowship, Hematology and Medical Oncology, 2007 - 2010
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2004 - 2007- University of South Florida College of MedicineClass of 2004
Certifications & Licensure
FL State Medical License 2010 - 2028
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification PowerChart (CQM), Cerner Corporation, 2017
- CMS Meaningful Use Stage 1 Certification PowerChart (Clinical), Cerner Corporation, 2017
- CMS Meaningful Use Stage 1 Certification HealtheLife and PowerChart, Cerner Corporation, 2017
Clinical Trials
- Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma Start of enrollment: 2009 Jun 18
- Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD) Start of enrollment: 2010 Apr 01
- Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease Start of enrollment: 2011 Mar 01
Publications & Presentations
PubMed
- Single center evaluation of a composite risk assessment model to predict non-relapse mortality following allogeneic hematopoietic cell transplantation (HCT).Reshma Ramlal, Jongphil Kim, Zachary Thompson, Leonel Ochoa-Bayona, Asmita Mishra
Bone Marrow Transplantation. 2026-04-08 - Donor type outcomes in setting of PTCy: more apparent than real?Joseph A Pidala, Ravi Varadhan, Richard J Jones
Blood Advances. 2026-03-24 - 2 citationsAccess to Allogeneic Cell Transplantation Based on Donor Search Prognosis: BMT CTN 1702 Trial.Jason G Dehn, Brent Logan, Stephanie J Lee, Bronwen E Shaw, Steven Devine
Transplantation and Cellular Therapy. 2026-03-01
Abstracts/Posters
- Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizu...Joseph Pidala, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts OutcomeJoseph Pidala, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Human CD83 Targeted Chimeric Antigen Receptor T Cell for the Prevention of Graft Versus Host Disease and Treatment of Myeloid LeukemiaJoseph Pidala, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
- Phase 1 Trial Demonstrates Encouraging Clinical Benefit and Promising Safety Profile of Pacritinib for the Prevention of Graft-Versus-Host Disease Published in Clinical Cancer ResearchMarch 22nd, 2021
Several Factors May Affect Immune Suppression Discontinuation After HCTSeptember 26th, 2019
Race, Ethnicity Affect Likelihood of Finding a Suitable Unrelated Stem Cell Donor for Cancer PatientsSeptember 11th, 2012
Grant Support
- Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical Centers - UG1H. LEE MOFFITT CANCER CTR & RES INST2011–2031
- Ustekinumab for Graft versus Host Disease Prevention (IND 144540)FRED HUTCHINSON CANCER CENTER2020–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
